Recursion Pharmaceuticals EBITDA 2020-2025 | RXRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Recursion Pharmaceuticals ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Recursion Pharmaceuticals ebitda from 2020 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.1B
Amgen (AMGN)	$155.2B
Gilead Sciences (GILD)	$148.5B
Vertex Pharmaceuticals (VRTX)	$94B
Bristol Myers Squibb (BMY)	$93.5B
CSL (CSLLY)	$82.7B
GSK (GSK)	$77.1B
Regeneron Pharmaceuticals (REGN)	$60.8B
Alnylam Pharmaceuticals (ALNY)	$57.5B
Argenex SE (ARGX)	$40.5B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$21.1B
Insmed (INSM)	$20.8B
Biogen (BIIB)	$19.2B
Incyte (INCY)	$15.3B
Illumina (ILMN)	$14.5B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$13.7B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Moderna (MRNA)	$10.2B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$7.9B
Roivant Sciences (ROIV)	$7.8B
Exact Sciences (EXAS)	$7.8B
Halozyme Therapeutics (HALO)	$7.8B